- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The HER-2 Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global HER-2 Targeted Drugs for Breast Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the HER-2 Targeted Drugs for Breast Cancer global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Trastuzumab segment is altered to a % CAGR between 2022 and 2028.
Global key companies of HER-2 Targeted Drugs for Breast Cancer include Roche, Chugai Pharmaceutical, GlaxoSmithKline, Novartis, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
HER-2 Targeted Drugs for Breast Cancer market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other
Market segment by players, this report covers
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe HER-2 Targeted Drugs for Breast Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of HER-2 Targeted Drugs for Breast Cancer, with revenue, gross margin and global market share of HER-2 Targeted Drugs for Breast Cancer from 2019 to 2022.
Chapter 3, the HER-2 Targeted Drugs for Breast Cancer competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and HER-2 Targeted Drugs for Breast Cancer market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe HER-2 Targeted Drugs for Breast Cancer research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of HER-2 Targeted Drugs for Breast Cancer
1.2 Classification of HER-2 Targeted Drugs for Breast Cancer by Type
1.2.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2021
1.2.3 Trastuzumab
1.2.4 Pertuzumab
1.2.5 Lapatinib
1.2.6 Neratinib
1.2.7 Trastuzumab Emtansine
1.2.8 Pyrotinib
1.2.9 Other
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market by Application
1.3.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global HER-2 Targeted Drugs for Breast Cancer Market Size & Forecast
1.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast by Region
1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region, (2017-2022)
1.5.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)
1.5.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)
1.5.6 South America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 HER-2 Targeted Drugs for Breast Cancer Market Drivers
1.6.2 HER-2 Targeted Drugs for Breast Cancer Market Restraints
1.6.3 HER-2 Targeted Drugs for Breast Cancer Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.1.4 Roche HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Chugai Pharmaceutical
2.2.1 Chugai Pharmaceutical Details
2.2.2 Chugai Pharmaceutical Major Business
2.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.2.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Chugai Pharmaceutical Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.4.4 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.5.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 CANbridge
2.6.1 CANbridge Details
2.6.2 CANbridge Major Business
2.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.6.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 CANbridge Recent Developments and Future Plans
2.7 Puma Biotechnology
2.7.1 Puma Biotechnology Details
2.7.2 Puma Biotechnology Major Business
2.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.7.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Puma Biotechnology Recent Developments and Future Plans
2.8 Hengrui Medicine
2.8.1 Hengrui Medicine Details
2.8.2 Hengrui Medicine Major Business
2.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.8.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Hengrui Medicine Recent Developments and Future Plans
2.9 Beacon Pharmaceuticals Limited
2.9.1 Beacon Pharmaceuticals Limited Details
2.9.2 Beacon Pharmaceuticals Limited Major Business
2.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.9.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Beacon Pharmaceuticals Limited Recent Developments and Future Plans
2.10 Hetero Drugs
2.10.1 Hetero Drugs Details
2.10.2 Hetero Drugs Major Business
2.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.10.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Hetero Drugs Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 HER-2 Targeted Drugs for Breast Cancer Players Market Share in 2021
3.2.2 Top 10 HER-2 Targeted Drugs for Breast Cancer Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 HER-2 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided
3.4 HER-2 Targeted Drugs for Breast Cancer Mergers & Acquisitions
3.5 HER-2 Targeted Drugs for Breast Cancer New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2017-2022)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2017-2022)
5.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)
6.2 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
6.3.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)
6.3.2 United States HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
6.3.3 Canada HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
6.3.4 Mexico HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)
7.2 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country
7.3.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)
7.3.2 Germany HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
7.3.3 France HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
7.3.4 United Kingdom HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
7.3.5 Russia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
7.3.6 Italy HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)
8.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)
8.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region
8.3.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2017-2028)
8.3.2 China HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8.3.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8.3.4 South Korea HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8.3.5 India HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
8.3.7 Australia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)
9.2 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)
9.3 South America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
9.3.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)
9.3.2 Brazil HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
9.3.3 Argentina HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2028)
10.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2028)
10.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country
10.3.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2028)
10.3.2 Turkey HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
10.3.4 UAE HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market HER-2 Targeted Drugs for Breast Cancer Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Region (2017-2022)
Table 5. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 9. Roche HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 11. Chugai Pharmaceutical Major Business
Table 12. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 13. Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 17. GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 21. Novartis HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Pfizer Corporate Information, Head Office, and Major Competitors
Table 23. Pfizer Major Business
Table 24. Pfizer HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 25. Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. CANbridge Corporate Information, Head Office, and Major Competitors
Table 27. CANbridge Major Business
Table 28. CANbridge HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 29. CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Puma Biotechnology Corporate Information, Head Office, and Major Competitors
Table 31. Puma Biotechnology Major Business
Table 32. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 33. Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Hengrui Medicine Corporate Information, Head Office, and Major Competitors
Table 35. Hengrui Medicine Major Business
Table 36. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 37. Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Beacon Pharmaceuticals Limited Corporate Information, Head Office, and Major Competitors
Table 39. Beacon Pharmaceuticals Limited Major Business
Table 40. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 41. Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Hetero Drugs Corporate Information, Head Office, and Major Competitors
Table 43. Hetero Drugs Major Business
Table 44. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product and Solutions
Table 45. Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of HER-2 Targeted Drugs for Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. HER-2 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided
Table 50. HER-2 Targeted Drugs for Breast Cancer Mergers & Acquisitions in the Past Five Years
Table 51. HER-2 Targeted Drugs for Breast Cancer New Entrants and Expansion Plans
Table 52. Global HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) by Type (2017-2022)
Table 53. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Type (2017-2022)
Table 54. Global HER-2 Targeted Drugs for Breast Cancer Revenue Forecast by Type (2023-2028)
Table 55. Global HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022)
Table 56. Global HER-2 Targeted Drugs for Breast Cancer Revenue Forecast by Application (2023-2028)
Table 57. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)
Table 58. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)
Table 59. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)
Table 60. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)
Table 61. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)
Table 62. North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2023-2028) & (USD Million)
Table 75. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)
Table 76. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)
Table 77. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)
Table 78. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)
Table 79. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)
Table 80. South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. HER-2 Targeted Drugs for Breast Cancer Picture
Figure 2. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2021
Figure 3. Trastuzumab
Figure 4. Pertuzumab
Figure 5. Lapatinib
Figure 6. Neratinib
Figure 7. Trastuzumab Emtansine
Figure 8. Pyrotinib
Figure 9. Other
Figure 10. HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application in 2021
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Drug Center Picture
Figure 14. Other Picture
Figure 15. Global HER-2 Targeted Drugs for Breast Cancer Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 16. Global HER-2 Targeted Drugs for Breast Cancer Revenue and Forecast (2017-2028) & (USD Million)
Figure 17. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2017-2028)
Figure 18. Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region in 2021
Figure 19. North America HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Europe HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. South America HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. HER-2 Targeted Drugs for Breast Cancer Market Drivers
Figure 25. HER-2 Targeted Drugs for Breast Cancer Market Restraints
Figure 26. HER-2 Targeted Drugs for Breast Cancer Market Trends
Figure 27. Roche Recent Developments and Future Plans
Figure 28. Chugai Pharmaceutical Recent Developments and Future Plans
Figure 29. GlaxoSmithKline Recent Developments and Future Plans
Figure 30. Novartis Recent Developments and Future Plans
Figure 31. Pfizer Recent Developments and Future Plans
Figure 32. CANbridge Recent Developments and Future Plans
Figure 33. Puma Biotechnology Recent Developments and Future Plans
Figure 34. Hengrui Medicine Recent Developments and Future Plans
Figure 35. Beacon Pharmaceuticals Limited Recent Developments and Future Plans
Figure 36. Hetero Drugs Recent Developments and Future Plans
Figure 37. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Players in 2021
Figure 38. HER-2 Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 39. Global Top 3 Players HER-2 Targeted Drugs for Breast Cancer Revenue Market Share in 2021
Figure 40. Global Top 10 Players HER-2 Targeted Drugs for Breast Cancer Revenue Market Share in 2021
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 42. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Type in 2021
Figure 43. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Type (2023-2028)
Figure 44. Global HER-2 Targeted Drugs for Breast Cancer Revenue Share by Application in 2021
Figure 45. Global HER-2 Targeted Drugs for Breast Cancer Market Share Forecast by Application (2023-2028)
Figure 46. North America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)
Figure 47. North America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)
Figure 48. North America HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)
Figure 49. United States HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Canada HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Mexico HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Europe HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)
Figure 53. Europe HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)
Figure 54. Europe HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)
Figure 55. Germany HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. France HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. United Kingdom HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Russia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Italy HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)
Figure 61. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)
Figure 62. Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Region (2017-2028)
Figure 63. China HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Japan HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South Korea HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. India HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Southeast Asia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Australia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)
Figure 70. South America HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)
Figure 71. South America HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)
Figure 72. Brazil HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Argentina HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Type (2017-2028)
Figure 75. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Sales Market Share by Application (2017-2028)
Figure 76. Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Country (2017-2028)
Figure 77. Turkey HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. UAE HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
